Back to Search
Start Over
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
- Source :
- Leukemia & Lymphoma; 55(5), pp 1206-1208 (2014)
- Publication Year :
- 2013
- Publisher :
- Informa UK Limited, 2013.
-
Abstract
- The Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial (MCL5) was launched in 2011 (EudraCT 2011-001557-85), aimed to improve the outcome of younger patients with MCL with high Mantle Cell Lymphoma...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Treatment outcome
ComputingMilieux_LEGALASPECTSOFCOMPUTING
Lymphoma, Mantle-Cell
Antibodies, Monoclonal, Murine-Derived
03 medical and health sciences
0302 clinical medicine
High dose cytarabine
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Treatment Failure
Hematology
business.industry
Cytarabine
medicine.disease
3. Good health
Lymphoma
First line treatment
Treatment Outcome
Cancer and Oncology
030220 oncology & carcinogenesis
Immunology
Rituximab
Mantle cell lymphoma
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 55
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....b758e75bffdfcae0b8a19ada30abc041